옵션 체인은 다양한 행사가격과 만기일에 대한 Nephros의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Nephros에 대한 시장 심리를 평가합니다..

Nephros (NASDAQ:NEPH) 주식, 옵션 체인

Nephros

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Nephros Inc

WIIM

AGCO

NEPH

Shares of machinery companies are trading higher amid ongoing volatility, possibly related to tariff delays.

Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) with a Speculative Buy and maintains $5 price target.

News

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $3.500 million which beat the analyst consensus estimate of $3.499 million by 0.03 percent. This is a 6.47 percent decrease over sales of $3.742 million the same period last year.

Earnings

Earnings Beats

Nephros Q3 2024 GAAP EPS $0.02 Beats $(0.02) Estimate, Sales $3.500M Beat $3.499M Estimate

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly sales of $3.50 million which met the analyst consensus estimate. This is a 6.47 percent decrease over sales of $3.74 million the same period last year.

Nephros Q3 Sales $3.50M Inline

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 200 percent. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $3.25 million which missed the analyst consensus estimate of $3.86 million by 15.75 percent. This is a 8.27 percent decrease over sales of $3.54 million the same period last year.

Nephros Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $3.25M Miss $3.86M Estimate

The Dow Jones index closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Nephros</h3>
<ul>
<li>The Trade: Nephros, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) Director Arthur H Amron <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 5,000 shares</a> at an average price of $2.24. To acquire these shares, it cost around $11,176.</li>
<li>What's Happening: On May 9, Nephros posted a narrower-than-expected quarterly loss.</li>
<li>What Nephros Does: Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets.</li>
</ul>
<h3 class="wp-block-heading">Presidio Property Trust</h3>
<ul>
<li>The Trade: Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) CEO Jack Kendrick Heilbron <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,300 shares </a> at an average price of $0.80. To acquire these shares, it cost around $8,257.</li>
<li>What's Happening: On May 14, the company said net loss for the three months ended March 31, 2024 was approximately $5.8 million, or 47 cents per basic and diluted share.</li>
<li>What Presidio Property Trust Does: Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties.</li>
</ul>
<h3 class="wp-block-heading">GEE Group</h3>
<ul>
<li>The Trade: GEE Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOB#NYSE">JOB</a>) Director John Randall Waterfield <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 250,000 shares</a> at an average price of $0.36. The insider spent around $89,831 to buy those shares. </li>
<li>What's Happening: On May 15, GEE Group posted weaker-than-expected quarterly sales.</li>
<li>What GEE Group Does: GEE Group Inc is a provider of specialized staffing solutions across the United States.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/05/39085305/top-4-materials-stocks-you-may-want-to-dump-in-q2">Top 4 Materials Stocks You May Want To Dump In Q2</a>

Long Ideas

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

SQFT

GEE Group And 2 Other Stocks Under $3 Insiders Are Buying

Offerings

Nephros Files For Mixed Shelf Of Up To $50M

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $3.522 million which missed the analyst consensus estimate of $3.734 million by 5.68 percent. This is a 4.73 percent decrease over sales of $3.697 million the same period last year.

Earnings Misses

Nephros Q1 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $3.522M Miss $3.734M Estimate

Benchmark analyst Robert Wasserman upgrades Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) from Hold to Speculative Buy and announces $5 price target.

Upgrades

Benchmark Upgrades Nephros to Speculative Buy, Announces $5 Price Target

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Nephros missed estimated earnings by -200.0%, reporting an EPS of $-0.06 versus an estimate of $-0.02.
Revenue was up $742 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Nephros's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.35M</td>
<td>3.11M</td>
<td>3.68M</td>
<td>2.80M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.74M</td>
<td>3.54M</td>
<td>3.70M</td>
<td>2.56M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Nephros <a href="https://www.benzinga.com/quote/NEPH/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nephros: Q4 Earnings Insights

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly losses of $(0.060) per share which missed the analyst consensus estimate of $(0.030) by 100 percent. The company reported quarterly sales of $3.300 million which missed the analyst consensus estimate of $3.813 million by 13.47 percent. This is a 29.01 percent increase over sales of $2.558 million the same period last year.

Nephros Q4 2023 GAAP EPS $(0.060) Misses $(0.030) Estimate, Sales $3.300M Miss $3.813M Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CINT

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

HBIO

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that Nephros will report an earnings per share (EPS) of $-0.02. 
Nephros bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 2.59% drop in the share price the next day.
Here's a look at Nephros's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>8.0%</td>
<td>-1.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709748146_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Nephros were trading at $3.01 as of March 05. Over the last 52-week period, shares are up 201.13%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NEPH/earnings">To track all earnings releases for Nephros visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Nephros

<h3>Gainers</h3>
<ul>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock moved upwards by 41.0% to $0.9 during Monday's regular session. The market value of their outstanding shares is at $12.9 million. </li>
<li>Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) shares moved upwards by 18.7% to $17.45. The market value of their outstanding shares is at $388.0 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares increased by 15.77% to $40.29. The company's market cap stands at $40.3 billion. As per the press release, Q4 earnings came out today. </li>
<li>Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) stock moved upwards by 15.08% to $0.33. The company's market cap stands at $86.0 million. </li>
<li>Envirotech Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) shares rose 14.32% to $2.79. The market value of their outstanding shares is at $42.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) stock decreased by 11.0% to $2.09 during Monday's regular session. The market value of their outstanding shares is at $6.9 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares fell 10.17% to $1.68. The market value of their outstanding shares is at $5.2 million. </li>
<li>Dogness (Intl) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) stock decreased by 10.0% to $6.66. The market value of their outstanding shares is at $13.9 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock decreased by 9.13% to $1.09. The market value of their outstanding shares is at $10.4 million. </li>
<li>Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) stock decreased by 8.67% to $3.9. The company's market cap stands at $13.6 million. </li>
<li>Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) shares fell 7.26% to $3.45. The company's market cap stands at $36.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CLEU

DOGZ

EVTV

ISPO

JFBR

SNBR

TRNR

VEEE

WKHS

11 Consumer Discretionary Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) stock increased by 61.0% to $0.16 during Tuesday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) stock rose 28.91% to $2.14. The company's market cap stands at $26.7 million. </li>
<li>Dogness (Intl) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) shares increased by 25.07% to $4.21. The company's market cap stands at $8.4 million. </li>
<li>Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) stock increased by 19.23% to $0.76. The company's market cap stands at $35.9 million. </li>
<li>Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) shares rose 15.21% to $3.56. The market value of their outstanding shares is at $37.3 million. </li>
<li>Tupperware Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) shares rose 15.19% to $2.35. The market value of their outstanding shares is at $108.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PARTS iD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ID#AMEX">ID</a>) stock declined by 43.3% to $0.05 during Tuesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock decreased by 18.65% to $0.93. The company's market cap stands at $47.9 million. </li>
<li>Vroom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) stock decreased by 15.05% to $0.63. The market value of their outstanding shares is at $87.4 million. </li>
<li>Yoshitsu Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) stock fell 14.07% to $0.75. The market value of their outstanding shares is at $27.3 million. As per the news, the H1 earnings report came out 2 days ago. </li>
<li>BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) shares declined by 9.61% to $2.26. The company's market cap stands at $14.1 million. </li>
<li>JOANN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOAN#NASDAQ">JOAN</a>) stock fell 8.69% to $0.5. The market value of their outstanding shares is at $20.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTBD

GDHG

JOAN

TKLF

UXIN

VLCN

VNCE

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

Shares of Despegar.com, Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/desp#NYSE">DESP</a>) rose sharply during Wednesday&rsquo;s session after the company raised its FY23 financial guidance.
The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.
Despegar.com shares gained 16.4% to $9.90 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Shattuck Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sttk#NASDAQ">STTK</a>) jumped 127.5% to $4.80 after the company announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.</li>
<li>ReShape Lifesciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rsls#NASDAQ">RSLS</a>) shares gained 63.8% to $0.4110 after the company announced it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX.</li>
<li>C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) shares jumped 59% to $3.7199 after the company announced data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma. Following the update, Stifel analyst Bradley Canino upgraded C4 Therapeutics from Hold to Buy and raised the price target from $2 to $12.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares gained 38.3% to $0.2016 after declining 9% on Tuesday.</li>
<li>Innovative International Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ioac#NASDAQ">IOAC</a>) shares rose 36% to $11.66.</li>
<li>NextPlay Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtp#NASDAQ">NXTP</a>) shares gained 26% to $1.1708 after surging 29% on Tuesday.</li>
<li>Nephros, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neph#NASDAQ">NEPH</a>) rose 23% to $3.16.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) gained 21.7% to $5.95 after the company announced results for MitoCareX Bio with its drug discovery platform.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eose#NASDAQ">EOSE</a>) rose 21% to $1.35. Eos Energy and Pine Gate Renewables announced partnership expansion with a minimum additional volume Of 500MWH.</li>
<li>Photronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plab#NASDAQ">PLAB</a>) gained 18.7% to $25.66 following fourth-quarter results.</li>
<li>Mynaric AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myna#NASDAQ">MYNA</a>) shares surged 18.2% to $5.66 after the company received a $33 million order from Northrop Grumman.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) rose 17.2% to $2.4380 following first-quarter results.</li>
<li>Professional Diversity Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipdn#NASDAQ">IPDN</a>) gained 16% to $2.8899.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) shares gained 14% to $2.8254. Aurora Mobile said its subsidiary Wuhan SendCloud Technology Co., Ltd. has entered into a strategic partnership with Beijing Muhua Information Technology Co., Ltd.</li>
<li>ABM Industries Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>) surged 13.6% to $50.38 after the company reported better-than-expected fourth-quarter financial results and issued guidance.</li>
<li>LQR House Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqr#NASDAQ">LQR</a>) rose 9.5% to $1.4126. LQR House announced its new marketing campaign for Soda Jerk.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) gained 7.4% to $384.03 after the company announced results from its Phase 2 study of VX-548 for the treatment of painful diabetic peripheral neuropathy.</li>
<li>REV Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/revg#NYSE">REVG</a>) gained 7.3% to $18.31 following upbeat quarterly results.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) rose 6.3% to $51.96. Cal-Maine has temporarily ceased production at a facility in Kansas following an outbreak of avian influenza at the site.</li>
<li>Take-Two Interactive Software, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttwo#NASDAQ">TTWO</a>) shares rose 3.5% to $162.64. Take-Two will be added to the Nasdaq-100 Index, effective prior to market open on Monday, Dec. 18, 2023.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Hywin Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hyw#NASDAQ">HYW</a>) shares fell 46.6% to $3.0001.</li>
<li>Boqii Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bq#NYSE">BQ</a>) declined 33.3% to $0.6670.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) fell 32.2% to $0.5497 as the company announced outcomes from meeting with the FDA regarding the company&#39;s next Phase 2 study supporting the advancement of next generation capecitabine for cancer patients.</li>
<li>Loop Media, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lptv#NASDAQ">LPTV</a>) fell 28.3% to $0.9246 following fourth-quarter results.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) declined 27% to $0.1415. TC BioPharm announced plan to implement ADS ratio change.</li>
<li>SRIVARU Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svmh#NASDAQ">SVMH</a>) fell 25.5% to $0.3051.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/whlr#NASDAQ">WHLR</a>) fell 24.6% to $0.2637.</li>
<li>Green Giant Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gge#NASDAQ">GGE</a>) fell 18.8% to $0.0690. Green Giant recently announced pricing of its public offering.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlgs#NASDAQ">WLGS</a>) fell 16.2% to $0.46 after gaining 7% on Tuesday.</li>
<li>Blackboxstocks Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blbx#NASDAQ">BLBX</a>) fell 15.8% to $3.24. Blackboxstocks announced it executed a definitive agreement to acquire Evtec Aluminium Limited.</li>
<li>IN8bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) shares fell 10.8% to $1.46 after jumping 28% on Tuesday. IN8bio recently announced updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.</li>
<li>Target Hospitality Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/th#NYSE">TH</a>) declined 11% to $9.74 as the company lowered its FY23 guidance.</li>
<li>Medifast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/med#NYSE">MED</a>) fell 9% to $68.66. LifeMD announced a strategic alliance with Medifast to offer transformative weight management solution.</li>
<li>Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) declined 8.8% to $26.07 after the company provided FY24 guidance.</li>
<li>JetBlue Airways Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jblu#NASDAQ">JBLU</a>) fell 6.2% to $5.20.</li>
<li>Southwest Airlines Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/luv#NYSE">LUV</a>) fell 6% to $28.51. Southwest Airlines sees fourth-quarter unit revenues to be down 9%-10% vs. prior view of down 9%-11%.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/23/12/36196130/dont-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurat"> Don&#39;t Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts</a>

Small Cap

Intraday Update

BLBX

CALM

CCCC

DESP

EOSE

INAB

IOAC

IPDN

JBLU

LPTV

MYNA

NXTP

PCSA

PLAB

REVG

RSLS

SPRC

STTK

SVMH

TCBP

TTWO

VRTX

WHLR

WLGS

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) shares increased by 18.3% to $38.45 during Tuesday's regular session. The company's market cap stands at $4.3 billion. </li>
<li>Gaotu Techedu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) stock rose 15.52% to $3.38. The company's market cap stands at $882.3 million. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares moved upwards by 13.61% to $0.95. The company's market cap stands at $152.4 million. </li>
<li>Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) shares moved upwards by 13.15% to $2.48. The company's market cap stands at $25.9 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) stock rose 10.22% to $1.18. The market value of their outstanding shares is at $447.0 million. </li>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock increased by 9.41% to $5.06. The market value of their outstanding shares is at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares decreased by 40.5% to $1.32 during Tuesday's regular session. The market value of their outstanding shares is at $6.0 million. </li>
<li>Esports Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMBLP#NASDAQ">GMBLP</a>) shares declined by 36.71% to $1.71. </li>
<li>Kaival Brands Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) stock declined by 25.39% to $0.18. The company's market cap stands at $10.7 million. </li>
<li>Farfetch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTCH#NYSE">FTCH</a>) stock declined by 22.16% to $0.57. The market value of their outstanding shares is at $224.8 million. </li>
<li>Harbor Custom Dev (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCDIP#NASDAQ">HCDIP</a>) stock decreased by 21.11% to $0.95. </li>
<li>Harbor Custom Dev (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCDI#NASDAQ">HCDI</a>) shares declined by 19.88% to $0.55. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAVA

CJET

DBGI

FTCH

GMBLP

GSX Techedu Inc. American Depositary Shares

GOTU

HCDI

Harbor Custom Development, Inc. - 8.0% Series A Cumulative Convertible Preferred Stock, no par value

HCDIP

KAVL

NEGG

The Dow Jones index closed higher by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Nephros </h3>
<ul>
<li>The Trade: Nephros, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neph#NASDAQ">NEPH</a>) Director, President and CEO Robert R. Banks Jr. <a href="https://www.benzinga.com/quote/NEPH/analyst-ratings"> acquired a total of 18,000 shares </a> an average price of $2.20. To acquire these shares, it cost around $39,647.</li>
<li>What&rsquo;s Happening: On Nov. 8, Nephros posted better-than-expected quarterly results.</li>
<li>What Nephros Does: Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets.</li>
</ul>
<h3>Delcath Systems</h3>
<ul>
<li>The Trade: Delcath Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcth#NASDAQ">DCTH</a>) CEO Gerard Michel <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 34,000 shares </a> at an average price of $2.94. To acquire these shares, it cost around $99,960.</li>
<li>What&rsquo;s Happening: On Nov. 13, Delcath Systems posted downbeat quarterly results.</li>
<li>What Delcath Systems Does: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/23/12/36175154/top-5-real-estate-stocks-that-may-implode-this-month"> Top 5 Real Estate Stocks That May Implode This Month </a>
<h3>Charles &amp; Colvard </h3>
<ul>
<li>The Trade: Charles &amp; Colvard, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cthr#NASDAQ">CTHR</a>) Director Ollin Sykes <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 61,898 shares </a> at an average price of $0.41. The insider spent around $25,286 to buy those shares.</li>
<li>What&rsquo;s Happening: On Nov. 9, Charles &amp; Colvard posted a wider quarterly loss.</li>
<li>What Charles &amp; Colvard Does: Charles &amp; Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market.</li>
</ul>
<h3>FTC Solar </h3>
<ul>
<li>The Trade: FTC Solar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftci#NASDAQ">FTCI</a>) Director Ahmad Chatila <a href="https://www.benzinga.com/quote/ERAS/analyst-ratings"> acquired a total of 13,960 shares </a> at an average price of $0.75. The insider spent around $10,470 to buy those shares.</li>
<li>What&rsquo;s Happening: FTC Solar recently appointed Anthony Carroll as Chairman of newly formed Customer Advisory Board.</li>
<li>What FTC Solar Does: FTC Solar Inc is a global provider of advanced solar tracker systems, supported by proprietary software and value-added engineering services.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Insider Trades

CTHR

DCTH

FTCI

Insiders Buying Delcath Systems And 3 Other Penny Stocks

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Nephros beat estimated earnings by 66.67%, reporting an EPS of $-0.02 versus an estimate of $-0.06.
Revenue was up $1.33 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 7.86% increase in the share price the next day.
Here's a look at Nephros's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.06</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.07</td>
<td>-0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.11M</td>
<td>3.68M</td>
<td>2.80M</td>
<td>2.62M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.54M</td>
<td>3.70M</td>
<td>2.56M</td>
<td>2.41M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Nephros <a href="https://www.benzinga.com/quote/NEPH/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nephros: Q3 Earnings Insights

Press Releases

Nephros Schedules Second Quarter 2024 Financial Results Conference Call

Nephros Announces Financial Results for Quarter Ended June 30, 2024

Nephros Delivers Critical Disaster Response to Support Hospitals and Care Facilities Impacted by Hurricanes Helene and Milton

General

Nephros Launches New HydraGuard 20" UltraFilter

Nephros Schedules Third Quarter 2024 Financial Results Conference Call

Nephros Announces Financial Results for Quarter Ended September 30, 2024

Comments

Nephros

Nephros (NEPH) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌